This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The proportions of CIA and the severity of anemia vary by region, cancer type, and stage.
- All of the approved drugs for CIA target the erythropoietin receptor. These drugs are all administered via both the intravenous and subcutaneous routes.
- There are only two industry-sponsored drugs in active clinical development for CIA, both of which are in Phase III. Therapies in development for CIA focus on targets such as iron and hypoxia-inducible factor-prolyl hydroxylase (HIF-PH). These drugs are administered via the intravenous and oral routes.
- The only high-impact upcoming event in the CIA space is topline Phase III trial results for roxadustat. The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 18.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 9.3 years in the overall hematology space.
- There have been only two licensing and asset acquisition deals involving CIA drugs during 2014-19. The values of the deals have not been disclosed.
- The distribution of clinical trials across Phase I-IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III-IV, and 39% in Phase I-II.
- Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 67 trials.
- Amgen leads industry sponsors with the highest number of clinical trials for CIA, followed by Johnson & Johnson.
Key Topics Covered:
2. Key Takeaways
3. Disease Background
- Disease definition
- Patient subtypes
- Risk factors
- Iron supplements
- Blood transfusion
- Erythropoietin-stimulating agents (ESAs)
6. Marketed Drugs
7. Pipeline Drugs
8. Key Upcoming Events
9. Key Regulatory Events
- Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive
10. Probability of Success
11. Licensing and Asset Acquisition Deals
12. Revenue Opportunity
13. Clinical Trial Landscape
- Sponsors by status
- Sponsors by phase
- Johnson & Johnson
For more information about this report visit https://www.researchandmarkets.com/r/eh189l